- Home
- AVDL vs TXO Comparison
AVDL vs TXO Comparison
Compare AVDL & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDL
- TXO
- Stock Information
- Founded
- AVDL 2015
- TXO 2012
- Country
- AVDL Ireland
- TXO United States
- Employees
- AVDL N/A
- TXO N/A
- Industry
- AVDL Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- AVDL Health Care
- TXO Energy
- Exchange
- AVDL Nasdaq
- TXO Nasdaq
- Market Cap
- AVDL 784.6M
- TXO 665.3M
- IPO Year
- AVDL 1996
- TXO 2023
- Fundamental
- Price
- AVDL $8.03
- TXO $16.92
- Analyst Decision
- AVDL Strong Buy
- TXO
- Analyst Count
- AVDL 7
- TXO 0
- Target Price
- AVDL $18.86
- TXO N/A
- AVG Volume (30 Days)
- AVDL 1.1M
- TXO 85.8K
- Earning Date
- AVDL 05-07-2025
- TXO 05-06-2025
- Dividend Yield
- AVDL N/A
- TXO 14.23%
- EPS Growth
- AVDL N/A
- TXO N/A
- EPS
- AVDL N/A
- TXO 0.65
- Revenue
- AVDL $169,117,000.00
- TXO $282,810,000.00
- Revenue This Year
- AVDL $50.53
- TXO $30.49
- Revenue Next Year
- AVDL $32.33
- TXO N/A
- P/E Ratio
- AVDL N/A
- TXO $26.03
- Revenue Growth
- AVDL 504.79
- TXO N/A
- 52 Week Low
- AVDL $6.38
- TXO $15.22
- 52 Week High
- AVDL $19.09
- TXO $23.56
- Technical
- Relative Strength Index (RSI)
- AVDL 54.47
- TXO 40.11
- Support Level
- AVDL $6.38
- TXO $16.15
- Resistance Level
- AVDL $8.22
- TXO $17.22
- Average True Range (ATR)
- AVDL 0.48
- TXO 0.93
- MACD
- AVDL 0.11
- TXO -0.10
- Stochastic Oscillator
- AVDL 89.67
- TXO 31.41
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.